Physician profile
Janet E Russell
NPI 1780691501
$12,358.84
in general payments reported to CMS, 2019-2025
41 companies · $2,064 in 2025
The $2,064 reported for 2025 was more than what 89% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,087 · 2020: $1,143 · 2021: $2,329 · 2022: $2,295 · 2023: $1,338 · 2024: $2,103 · 2025: $2,064.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,501 · Education: $3.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,501.12 |
| Education | $3.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,160.42 | 2019-2024 | Farxiga, Lokelma |
| Amgen INC. | $1,141.89 | 2019-2025 | Krystexxa, Tavneos, Parsabiv |
| Travere Therapeutics, INC. | $794.12 | 2022-2025 | |
| Fresenius USA Marketing, INC. | $711.43 | 2019-2025 | Velphoro, Velphoro |
| Opko Pharmaceuticals, LLC | $680.14 | 2019-2025 | Rayaldee |
| Bayer Healthcare Pharmaceuticals INC. | $673.15 | 2021-2025 | |
| Horizon Therapeutics Plc | $561.37 | 2019-2023 | Krystexxa |
| Otsuka America Pharmaceutical, INC. | $551.18 | 2019-2025 | Jynarque |
| Novartis Pharmaceuticals Corporation | $488.39 | 2019-2025 | |
| Vifor Pharma, INC. | $452.79 | 2019-2025 | Veltassa |
| Veloxis Pharmaceuticals, INC. | $430.47 | 2019-2025 | Envarsus |
| Aurinia Pharma U.S., INC. | $393.40 | 2021-2024 | Lupkynis |
| Daiichi Sankyo INC. | $368.50 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $357.02 | 2020-2025 | Acthar, Terlivaz |
| Akebia Therapeutics INC | $317.66 | 2019-2024 | Auryxia |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Janet Russell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.